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1 Supplemental Methods 
 
The GENIUS-CHD consortium builds on previous successful collaborations between individual 
investigator-led studies.1-3 We identified additional studies meeting eligibility criteria (listed below) 
through a combination of literature, article bibliography and conference abstract searches as well as 
established investigator networks. Principal investigators (PIs) were invited to participate in the GENIUS-
CHD consortium with membership remaining open to any study meeting eligibility criteria listed in 
Figure 1 (in the main manuscript).    
Terminology 
 
In this article and for future consortium analyses, we use the term “subsequent” to refer to all coronary 
and cardiovascular diagnoses, procedures or events including death that occur after enrolment into a 
study, which may be at the time of an index CHD event (for ACS studies) or later.   
Eligibility 
 
Studies were eligible to join the GENIUS-CHD consortium if they: 
1. Included individuals with established CHD.  CHD was defined as the presence of or history of acute 
coronary syndrome at baseline, or of coronary artery disease as evidenced by any revascularization 
procedure (percutaneous coronary intervention or bypass surgery) or demonstrable plaque in any 
epicardial vessel on direct coronary imaging. One study also included physician confirmed stable 
angina but only as part of a wider definition of established CHD.4   
2. Acquired prospective follow-up of participants with ascertainment of one or more subsequent 
cardiovascular disease events as well as all-cause mortality. No minimum time frame or person-
years of follow up was required.  
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3. Stored blood samples for these individuals, which are viable and suitable for DNA and/or biomarker 
analysis or have previously collected such data prior to sample depletion.   
Participating studies 
 
We list studies participating in the GENIUS-CHD consortium at the time in Table 1 of the main 
manuscript.  Please refer to www.genius-chd.org for an updated list. 
Following agreement to participate, each investigator submitted brief details about their study including 
study design, inclusion criteria and number of participants, available clinical and research phenotypes, 
sample availability and endpoints, using an online questionnaire with the results collated by the central 
analysis sites at University College London (UCL), UK and University Medical Centre (UMC) Utrecht, 
Netherlands.  Full details describing the majority of studies have been published individually, and 
PubMed IDs are listed in Table 1 of the main manuscript.   
Participating studies received local ethical committee approval, and all included patients who provided 
informed consent at the time of enrolment. The central analysis sites also received favourable ethical 
reviews for collating and analysing summary level data from these individual studies. 
Consortium management 
 
The consortium represents a voluntary collaboration between multiple studies and management is 
based on a set of principles outlined in a memorandum of understanding (available at www.genius-
chd.org).     
A scientific steering committee, comprising of at least one representative from each study, represents 
the consortium, and is the decision-making group for projects and consortium activity. A smaller 
4 
 
committee oversees operational and management aspects for the group.  Finally, smaller project-
specific working groups (PSWG) initiate, lead and run individual approved projects reporting to the main 
steering committee.  The overall structure of the consortium is presented in Figure 1 in the main 
manuscript.  More detail on the specific activities and membership of these subgroups is available at 
www.genius-chd.org.  
Approach to Analysis  
 
The consortium operates using a federated analysis approach whereby individual level data are analysed 
locally at each site using centrally developed and standardized statistical scripts, distributed to each 
group along with relevant instructions.  Thereafter, analysis teams from individual studies share 
summary level outputs with the central analysis sites for meta-analyses.  
For each study, a core standard dataset is first developed. Preparatory work conducted by the UCL/UMC 
Utrecht teams has ensured that standardized units and definitions are used for the variables of interest. 
Additionally, detailed and adaptable statistical scripts are available based on the open source statistical 
software package R,5 allowing additional projects to be initiated in a timely fashion and by a 
standardized and easily implementable workflow.  
Planned projects 
 
Projects to be prioritized by the consortium include core internal proposals, developed by the steering 
committee, as well as external proposals, either from consortium members seeking validation and 
replication of their own study findings, or from external investigators who wish to run a de novo project 
within the consortium. All new projects are subject to approval by the scientific steering committee 
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based on feasibility, interest and scientific value. Individual studies are entitled to opt in or out of the 
proposed analyses at the discretion of their respective principal investigators. 
Instructions and relevant information for submission of new proposals are on the website to guide 
investigators wishing to submit new proposals.  Leaders of approved projects are asked to nominate a 
PSWG and to report on progress at regular intervals to the steering committee.   
Future proposals will seek to perform de novo genotyping and run biomarker assays on stored samples. 
In such cases and wherever possible, core or central laboratories will be identified within each 
country/continent to facilitate this.  Sharing of individual level data or biological materials outside of the 
host institution, should it be required, will be subject to relevant and strict ethical and review board 
approvals from each site.  A major strength of the federated analysis approach is that it avoids the need 
for sharing individual level data, and only summary level estimates are shared, even though analyses 
have been performed using individual level data in a standardized way ensuring high quality and 
comparable results. This design also circumvents the need to transfer samples to a central processing 
site, avoiding ethical concerns associated with sending samples out of the country of origin. 
Feasibility analysis 
 
To help establish the consortium and demonstrate feasibility of this approach we developed an initial 
analysis plan, dataset of summary estimates and statistical script to collect descriptive data and examine 
the association of age, sex and smoking at baseline on the time to a primary outcome of subsequent 
CHD death or MI. Secondary endpoints included time to event: MI, revascularization, heart failure, 
stroke, ischemic stroke, CHD death, cardiovascular death, all cause death and a cardiovascular 
composite comprised of MI, revascularization, stroke or CV death. All time-to-event analyses were based 
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on a Cox proportional hazards model, with the proportional hazard assumption tested using a Chi-
square “goodness of fit” statistic.6 
Study-specific results were collected and central processing was performed jointly by the UMC Utrecht 
and UCL teams.  Point estimates (ORs or HRs) and their corresponding standard errors were meta-
analysed using the fixed effect inverse variance weighted method; random effects estimates are 
included in supplementary tables 5-7. Study specific proportional hazard tests were combined using 
Fisher’s method for p-value meta-analysis.7 All analyses at the coordinating centres were conducted 
using R statistical software (v 3.4.1).5 
 
  
7 
 
Brief cohort descriptions 
1) 4C - Clinical Cohorts in Coronary Disease Collaboration 
4C was a cohort study of 1,493 patients with coronary artery disease that ran between 2009 and 2014. 
The patients underwent deep clinical, metabolomic and genetic phenotyping for identification of novel 
prognostic markers. The median follow-up was 2.43 years. All study participants gave written informed 
consent.  
 
2) AGNES - Arrhythmia Genetics in the Netherlands   
AGNES consists of patients presenting with a first acute ST-segment elevation MI that survived to 
hospital admission. Patients were recruited at seven heart centers in the Netherlands between 2001 and 
2011. Individuals with an actual non-ST-segment elevation MI, prior MI, congenital heart defects, known 
structural heart disease, severe co-morbidity, electrolyte disturbances, trauma at presentation, recent 
surgery, previous coronary artery bypass graft or use of class I and III antiarrhythmic drugs. AGNES 
patients were of self-declared Dutch European descent. The Institutional Review Board of the Academic 
Medical Centre (University of Amsterdam) and other participating centres approved the AGNES study. 
All participants gave written informed consent 8.   
 
3) ANGES - Angiography and Genes Study 
The ANGES study population consists of 1,000 Finnish individuals who underwent coronary angiography 
at Tampere University Hospital to detect coronary artery disease between September 2002 and July 
2005. Data were collected on age, sex, body mass index, alcohol consumption, smoking, medication as 
well as traditional risk factors of atherosclerosis. A clinical diagnosis of myocardial infarction was based 
on symptoms, electrocardiographic findings and biochemical marker tests measuring troponin I 
and creatine kinase. Previous cardiovascular diseases, therapeutic procedures and data on coronary 
artery disease and myocardial infarction were retrieved from patient records at Tampere University 
Hospital. Follow-up data were derived from the national health care registers maintained by the 
National Institute for Welfare and Health. The local ethical committee has approved the study and a 
written informed consent was obtained from all participants  9.    
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4) ATVB - Italian Atherosclerosis, Thrombosis and Vascular Biology Group  
The ATVB study contributed 1,210 coronary heart disease cases to GENIUS analyses who were enrolled 
between January 1998 and January 2001. Cases were hospitalized for a first myocardial infarction before 
the age of 45 years and also underwent coronary arteriography at the time of hospitalization.  
Study participants were given a standardized questionnaire including information on cardiovascular risk 
factors, medical diagnosis, lifestyle, and medication with collected data including age, sex, and 
traditional risk factors such as a family history of ischemic heart disease, smoking, high serum 
cholesterol levels, diabetes, hypertension, and cocaine use. Alcohol intake and the levels and pattern of 
physical exercise were also recorded. All of the study participants agreed to give blood samples for DNA 
analysis and cholesterol measurements. The Institutional Review Boards of the participating hospitals 
approved the study, and the cases and controls gave their written informed consent 10. 
 
5) CABGenomics - Coronary Artery Bypass Genomics 
The CABG Genomics Research Study is a prospective, ongoing two institution collaborative study 
conducted by investigators at the Department of Anesthesiology at Brigham and Women’s Hospital, 
Boston, MA and at the Division of Cardiovascular Anesthesiology, Texas Heart Institute, St. Luke’s 
Episcopal Hospital, Houston, TX. To date enrolled >3000 subjects undergoing primary coronary artery 
bypass graft (CABG) surgery for the primary purpose of identifying important genetic predictors of 
adverse postoperative outcomes. The study has active Institutional Review Board approval and patients 
signed written informed consents 11. 
 
6) CardioLines 
CardioLines is a study aiming to investigate the potential factors relating to success or failure of 
diagnosis and treatment amongst cardiovascular patients. 
 
7) CDCS - Coronary Disease Cohort Study  
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The Coronary Disease Cohort Study (CDCS) is a cohort study of 2,140 patients with unstable angina or 
myocardial infarction admitted to Christchurch or Auckland Hospitals (New Zealand) from 2002-
2009. Inclusion criteria were ischaemic discomfort plus one or more ECG change (ST-segment 
depression or elevation >=0.5mm, T-wave inversion of >=3mm in >=3 leads or left bundle branch block), 
elevated levels of cardiac markers, a history or coronary disease, age >=65 years and a history or 
diabetes or vascular disease.  Patients were excluded if they had a severe comorbidity that reduced their 
life expectancy to <3 years. Anthropometric and clinical measures, including echocardiography and a 
large number of neurohormonal markers, were documented at baseline once patients were stable 
(approximately 1 month after hospital admission). Clinical outcomes were recorded by direct follow-up 
and from the New Zealand Health Information Service for a minimum of 3 years after 
admission (median 5 years, maximum 9.5 years). The study was approved by the New Zealand Multi-
region Ethics Committee (CTY/02/02/018) and all patients provided written informed consent. The study 
was registered on the Australian New Zealand Clinical Trials Registry (ACTRN12605000431628).  
 
8) COGEN - The Copenhagen Cardiovascular Genetic study 
COGEN is a biobank of around 80,000 individuals recruited from six cardiology departments across 
Copenhagen, Denmark between 2010 and 2017.  
 
9) COROGENE 
COROGENE was a cohort of consecutive Finnish patients undergoing coronary angiogram between June 
2006 and March, 2008 (n=5330), collected in the Helsinki University Central Hospital. The controls for 
COROGENE cases were selected from the greater Helsinki region participating for FINRISK 1997, 2002, 
and 2007 cohorts. All participants provided written informed consent 12.  
 
10) CTMM - Circulating Cells 
The Center for Translational Molecular Medicine (CTMM) – Circulating Cells is a prospective cohort 
study conducted in four Dutch medical centers. Between March 2009 and September 2011, the study 
enrolled 730 patients with stable or unstable angina pectoris undergoing coronary angiography. Details 
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on the study design have been described elsewhere 13. Median follow-up was 300 days. Cardiovascular 
events during follow-up were verified by a clinical event committee. The study was approved by the 
ethical committees of the participating hospitals and was conducted in accordance with the Declaration 
of Helsinki.  
 
11) CURE 
CURE was an international, multicentre, randomized, parallel group trial of the combination of 
clopidogrel plus aspirin vs placebo plus aspirin in patients with acute coronary syndrome (unstable 
angina and non-Q wave myocardial infarction). The study involved 12,562 patients from 508 centres 
across 28 countries 14, 15. 
 
12) EGCUT - Estonian Biobank 
The  Estonian  Biobank  is  a  population-based  biobank  of  the Estonian  Genome  Center  at  the 
Institute  of  Genomics,  University  of  Tartu (www.biobank.ee; EGCUT).  The  entire  project  is 
conducted  according  to  the  Estonian  Gene Research  Act  and  all  of the  participants  have signed  
the  broad  informed  consent.  The  cohort  size  is  up  to 52,000  individuals  from  18  years of  age  
and  up,  closely  reflecting  the  age,  sex  and  geographical distribution  of  the  Estonian population.  
All  of  the  subjects  were  recruited  randomly  by general  practitioners  and physicians  between  2002  
and  2011.  A  Computer  Assisted  Personal  interview  was  filled within  1-2  hours  at  a  doctor’s  
office,  including  personal,  genealogical,  educational, occupational  history  and  lifestyle  data.  
Anthropometric  measurements,  blood  pressure  and resting  heart  rate  were  measured  and  venous  
blood  taken  during the  visit.  Medical  history and  current  health  status is  recorded  according  to  
ICD-10 codes  and  the  data  are continuously  updated through  periodical  linking  to  national  
electronic  databases  and registries.  
Prevalent  and  incident  CHD  cases  (n=2700)  for  this case-cohort  study  were obtained  via  linkage  to  
the  Estonian  Health  Insurance  Fund  (EHIF)  database  and  the  Estonian Causes  of  Death  Registry.  
The  mean  follow-up  time  for  this  sample  set  is  6.6  years  (SD  3.0 years)  and  median  follow-up  
time  6.7  years. 
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13) EMORY - Emory Cardiovascular Biobank 
The Emory Cardiovascular Biobank is a prospective cohort of 5,876 patients undergoing elective or 
emergent heart catheterization for suspected or confirmed CAD at 3 Emory healthcare sites in Atlanta, 
GA. Subjects with congenital heart disease and heart transplantation cancer were excluded. The study 
was approved by the Institutional Review Board at Emory University, Atlanta, GA, USA. All subjects 
provided written informed consent at the time of enrolment. 
 
14) ERICO - Estratégia de Registro de Insuficiencia Coronariana 
ERICO was a community hospital registry of 839 (mean age = 63 years-old; 60% men) patients with a 
medical diagnosis of the acute coronary syndrome. They were referred to primary care setting or private 
physician to evaluate the impact of the “real world” concern to secondary cardiovascular prevention. 
The enrolment period was from 2009 to 2014. The follow-up used the cold and hot pursuit of events. 
The contact was by phone periodically according to the study design 16.  
 
15) FASTMI2005 – The French Registry of Acute ST-Elevation MI 
FAST-MI (French Registry of Acute ST-Elevation or non- ST-elevation Myocardial 
Infarction) 2005 (NCT00673036) was a nationwide French registry that consecutively included patients 
with STEMI or NSTEMI admitted to cardiac intensive care units (ICU) within 48 hours of symptom onset. 
The primary objective was to evaluate the characteristics, management, and outcomes of AMI patients, 
as seen in routine clinical practice, on a country-wide scale. Of all centres managing AMI patients in 
France , including university teaching hospitals, general and regional hospitals, and private clinics 
receiving AMI emergencies, 60% (223 centres, 3059 patients during one month period and 3670 patients 
overall) participated in the study between October and December 2005. AMI was defined by increased 
levels of cardiac biomarkers together with either compatible symptoms or ECG changes. Exclusion 
criteria were (1) refusal to participate; (2) iatrogenic MIs, defined as occurring within 48 hours of any 
therapeutic procedure and (3) AMI diagnosis invalidated in favour of another diagnosis. Follow-up 
information was collected through contacts with the patients’ physicians, the patients or their family, 
and registry offices of their places of birth. Events were adjudicated by a scientific committee whose 
members were unaware of patients’ genotypes. The study was conducted in accordance with the 
12 
 
guidelines on good clinical practice and French law. A written consent was obtained from all 
participants. Additional written consent was obtained for those participating in the DNA bank. The study 
protocol was reviewed by the relevant Committee for the Protection of Human Subjects (CPP). Data file 
collection and storage were approved by the Commission Nationale Informatique et Liberté 17.   
 
16) FINCAVAS - Finnish Cardiovascular Study 
The Finnish Cardiovascular Study (FINCAVAS) includes 4,567 patients who underwent exercise stress 
tests at Tampere University Hospital. Study participants were followed up for major cardiovascular 
events, coronary procedures and cause of death with follow-up data gathered at 2, 5 and 10 years post-
recruitment 18. 
 
17) FRISCII - Fast Revascularisation during Instability in Coronary artery disease  
The FRISC II study was a prospective randomised multicentre study of 3489 patients with non-ST-
elevation acute coronary syndrome performed in 58 Scandinavian hospitals. The trial compared long-
term (3 months) treatment with low molecular mass heparin (dalteparin = FRagmin) versus placebo and, 
in a factorial design, an early invasive versus a non-invasive treatment strategy. Outcome events were 
cardiovascular and total death, myocardial infarction, stroke and major bleeding. Complete follow-up 
with event adjudication was performed during the initial 2 years. Long-term follow-up by registries is 
available until 15 years. DNA for genetic analyses is available from 3606 patients. 
 
18) GENDEMIP - GENetic Determination of Myocardial Infarction in Prague 
Starting in 2004, data from men and women younger than 55 and 65 years, respectively, with acute 
coronary syndrome were collected from Coronary Care Unit at Clinic of Cardiology at Institute for 
Clinical and Experimental Medicine, Prague, Czech Republic. Information recorded included history of 
acute coronary syndrome, clinical course and procedures done at CCU. In addition, information 
regarding traditional cardiovascular risk factors including repeated measurements of nonfasting/fasting 
plasma lipids, glycemia and hsC-reactive protein during stay in hospital was obtained. In this population, 
samples for genetic analyses were collected. Patients were followed up in one year period on out-
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patient visit or on mailing basis. Since 2016 age limitation was lifted and the data were more focused on 
clinical parameters, including quality of life and heart insufficiency questionnaires. Laboratory and 
genetic methods were moderately expanded. The methodology is the same. The number of included 
patients is recently approximately 1,600 men and 650 women. Questionnaire and list of laboratory 
measurements are available. 
19) GENEBANK - Cleveland Clinic Genebank Study 
The Cleveland Clinic GeneBank study is a single site sample repository generated from consecutive 
patients undergoing elective diagnostic coronary angiography or elective cardiac computed tomographic 
angiography with extensive clinical and laboratory characterization and longitudinal 
observation.  Subject recruitment occurred between 2001 and 2007.  Ethnicity was self-reported and 
information regarding demographics, medical history, and medication use was obtained by patient 
interviews and confirmed by chart reviews.  All clinical outcome data were verified by source 
documentation.  CAD was defined as adjudicated diagnoses of stable or unstable angina, myocardial 
infarction (MI) (adjudicated definition based on defined electrocardiographic changes or elevated 
cardiac enzymes), angiographic evidence of ≥ 50% stenosis of one or more major epicardial vessel, 
and/or a history of known CAD (documented MI, CAD, or history of revascularization).  Prospective 
cardiovascular risk was assessed by the incidence of major adverse cardiac events (MACE) during three 
years of follow-up from the time of enrollment, which included nonfatal MI, nonfatal stroke, and all-
cause mortality.  Nonfatal events were defined as MI or stroke in patients who survived at least 48 hours 
following the onset of symptoms.  Adjudicated outcomes ascertained over the ensuing 3 years for all 
subjects following enrollment were confirmed using source documentation.  The GeneBank Study has 
been used previously for discovery and replication of novel genes and risk factors for atherosclerotic 
disease (refs given above). The present analysis included ~3703 Caucasian subjects for whom imputed 
genotype and CAD-related outcome data were available, depending on the phenotype in question. 
 
20) GENESIS-PRAXY 
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GENESIS-PRAXY was a prospective, multicenter study of 1,210 patients aged 18-55 years and admitted 
to hospital with ACS. At baseline, questionnaires were administered, and anthropometric and biological 
measurements were performed. The patients were observed for at least 1 year, with additional 
questionnaires being administered at 1, 6, and 12 months post-discharge. A review of medical records 
were performed both at baseline and during follow-up 19. 
 
21) GENOCOR – Genetic Mapping for Assessment of Cardiovascular Risk 
The Italian GENOCOR (Genetic Mapping for Assessment of Cardiovascular Risk) study, included 1000 
patients who were discharged between 1999 and 2007 with a diagnosis of ischaemic heart disease with 
patients given the option of voluntary genetic screening. Patients were eligible for inclusion in GENIUS 
analyses if they had all genotyping data and completed follow-up. The final cohort comprised 498 
patients: 315 with MI and 183 with angina. The study was approved by the local ethics committee and 
written informed consent was obtained in all patients 20. 
 
22) GEVAMI - The GEnetic causes to Ventricular Arrhythmia in patients during first 
ST-elevation Myocardial Infraction 
The GEVAMI study is an ongoing prospective Danish case-control study among patients with first ST-
elevation myocardial infarction (STEMI) between the ages of 18 and 80 years.(PMID:25559012) Cases are 
patients who experienced onset of ventricular fibrillation (VF) within the first 12 hours of symptoms of 
STEMI before guided catheter insertion for primary percutaneous coronary intervention (PPCI), and 
controls did not have VF during this time period or during PPCI. Baseline demographics and previous 
medical history are collected by research coordinators utilizing pre-designed questionnaires and whole 
blood is collected for genetic analysis. Follow-up on the patients is done by the Danish registries. 
 
23/24) GoDARTS incident/prevalent  
The Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) cohort profile has been 
described previously 21. At the point of recruitment, all participants in GoDARTS provided, by invitation, 
informed consent for their data to be used for research purposes and explicit consent for use in 
collaboration with industry. The study complies with the Declaration of Helsinki. 
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25/26) GRACE_Belgium & GRACE_UK - Global Registry of Acute Coronary Events  
The GRACE Genetics Study consists of the 3473 patients from whom DNA was collected by the eight 
participating centres in three countries (UK, Belgium, and Poland) between May 2001 and June 2007. 
Collected blood samples were transferred to the core laboratory (The Queens Medical Research 
Institute, Edinburgh, UK), where DNA was extracted and stored at minus 80C. 
Patients were eligible if they were admitted to participating hospitals with a clinical diagnosis of ACS and 
at least one of the following features: electrocardiographic changes consistent with ACS, increases in 
serum biochemical markers of cardiac necrosis, documented prior MI; congestive heart failure believed 
to be due to ischaemia or resuscitated sudden death; history of/or new positive stress test or angina, 
with or without imaging; prior or new cardiac catheterization documenting artery disease, percutaneous 
coronary intervention (PCI), or coronary artery bypass graft (CABG)], or both. 
To ensure enrolment of an unselected ACS population, sites recruited the first 10–20 consecutive 
eligible patients each month. Regular audits were performed at all participating hospitals to confirm 
conformance to eligibility criteria and correct interpretation of data in the case report form. Trained 
study coordinators collected data using standardized case report forms. 
Demographic characteristics, medical history, presenting symptoms, duration of pre-hospital delay, 
biochemical and electrocardiographic findings, treatment practices, and outcomes were collected. All 
cases were assigned to one of the following categories using predefined criteria: (i) STEMI (including left 
bundle-branch block), (ii) non-STEMI, (iii) UA, and (iv) other cardiac or (v) non-cardiac diagnoses 22, 23.  
 
27) IDEAL - Incremental Decrease in End Points Through Aggressive lipid Lowering  
The IDEAL RCT was a prospective, randomized, open-label, blinded end-point evaluation, multicentre 
study of the occurrence of cardiovascular   
events in patients treated with atorvastatin 80 mg/d or usual-dose simvastatin 20 mg/d to lower LDL-
cholesterol as much as possible. Men or women up to 80 years of age either hospitalized with a definite 
acute myocardial infarction or with a history of definite myocardial infarction, eligible for statin therapy 
according to recent national guidelines 24. 
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28) INTERMOUNTAIN - Intermountain Heart Collaborative Study 
The Intermountain Heart Collaborative Study is a registry encompassing a prospectively enrolled cohort 
of cardiac catheterization patients who electively, urgently, or emergently underwent coronary 
angiography for suspected coronary heart disease at the Intermountain Medical Center, LDS Hospital, 
and Cottonwood Hospital in Salt Lake City, Utah. The registry was established in 1994 and patient 
enrollment is ongoing.25, 26 All cohort members were treated per clinical guidelines for coronary artery 
disease and myocardial infarction depending on the findings of angiography and other diagnostic 
testing, with treatments including revascularization (i.e., percutaneous coronary intervention or 
coronary bypass surgery) with medical therapy, or medical therapy alone. Cohort follow-up used passive 
surveillance of electronic health records from Intermountain Healthcare’s network of 22 hospitals and 
>180 clinics in Utah and southeast Idaho, a geography in which Intermountain serves the healthcare 
needs of approximately two thirds of the population. Mortality was determined from those records, 
Utah death certificates, and the Social Security death master file. 
 
29) INVEST - INternational VErapamil SR Trandolapril Study Genetic Substudy 
 INVEST (INternational VErapamil SR Trandolapril STudy) was an international, multicenter, randomized 
controlled clinical trial of 22,576 hypertensive individuals with documented coronary artery disease of 
≥50 years old 27. Patients were randomized to either a calcium channel blocker (Verapamil SR)-based 
treatment strategy (CCB strategy) or a β-blocker (atenolol)-based treatment strategy (β-blocker 
strategy), with HCTZ and trandolapril available as add-on agents in both strategies. The 
genetic substudy of INVEST (INVEST-GENES) includes DNA samples from 5,979 INVEST participants from 
the United States, including Puerto Rico. All study protocols were approved by local or central 
institutional review boards and all participants provided separate, voluntary, written informed consent 
for participation in INVEST and INVEST-GENES.   
 
30) JUMC - Krakow-GENIUS-CHD 
Between 2010-2015 in Jagiellonian University Medical College (Krakow, Poland), patients were enrolled 
into one of the two following studies: VISION (Vascular Events in Noncardiac Surgery Patients Cohort 
Evaluation study; 900 patients from Polish cohort undergoing vascular surgery) or LTIMI (Leukotrienes 
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and Thromboxane In Myocardial Infarction; 261 MI patients). Protocols for recruitment have been 
described elsewhere 28, 29. From these 2 cohorts, patients with documented coronary artery disease 
(both acute coronary syndromes and stable coronary artery disease) were eligible to participate in the 
GENIUS project (n=747). DNA samples for genetic analyses were available for 704 subjects 
(94%). Cardiovascular mortality was defined as any death related to cardiovascular reasons obtained in 
the follow-up, including: sudden cardiac death, fatal myocardial infarction, death due to congestive 
heart failure, or death immediately after intervention to treat CAD, as well as fatal stroke. The median 
follow-up of study participants was 360 days with 0.3% of the sample lost to follow-up. All patients 
signed written informed consent to participate according to the local ethics committee and with 
accordance with the Helsinki Declaration.  
 
31) KAROLA 
The KAROLA study is a prospective cohort study comprising subjects that were recruited in 1999 and 
2000 in two rehabilitation clinics in middle and southern Germany (Klinik am Südpark, Bad Nauheim; 
Schwabenland-Klinik, Isny-Neutrauchburg). All patients aged 30–70, who were undergoing inpatient 
cardiovascular rehabilitation in one of these clinics because of the recent occurrence of an acute 
cardiovascular event or procedure (acute coronary syndrome, acute myocardial infarction, coronary 
artery revascularisation) within the past 3 months before admission, were eligible for the study. Overall, 
the study included 1206 patients at baseline. The study protocol was approved by the ethics committees 
of the Universities of Ulm and Heidelberg, and by the ethics boards of the chambers of physicians of the 
federal states of Hessen and Baden-Wuerttemberg. Written informed consent was obtained from all 
participants before enrolment in the study. 
Health related and sociodemographic data were collected from patients with self-administered 
standardised questionnaires at baseline. Additional information on medical findings and secondary 
diagnoses was obtained from hospital medical records. During follow-up, primary care physicians of 
patients were contacted to obtain medical information and incidence of non-fatal cardiovascular events. 
For patients deceased during follow-up, death certificates were retrieved from local health authorities 
and the main cause of death was coded according to the current International Classification of Diseases 
(ICD). 
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32) LIFE-HEART - Leipzig Heart Study 
The LIFE-Heart study is an observational study of patients recruited at the Leipzig Heart Center, Germany. 
Patients with suspected coronary artery disease (CAD), stable CAD or myocardial infarction were 
recruited. Patients received a comprehensive assessment of vessel status and cardiologic function 
including coronary angiography, carotid ultrasound, ankle-brachial index, echo-cardiography and 
electrocardiography. Details of the study can be found in Beutner et al 30. Genotyping information 
including quality control can be found in Pott et al 31. 
The study was approved by the Ethics Committee of the Faculty of Medicine of Leipzig University, 
Germany (Reg. No 276-2005) and is registered at ClinicalTrials.gov (NCT00497887). Written informed 
consent was obtained from all participants included in the study. 
 
33) LURIC - The LUdwigshafen RIsk and Cardiovascular Health Study 
The Ludwigshafen Risk and Cardiovascular Health (LURIC) study is a monocentric hospital based 
prospective study including 3316 individuals referred for coronary angiography recruited in the 
Ludwigshafen Cardiac Center, southwestern Germany from 1997 – 2000 32. Clinical indications for 
angiography were chest pain or a positive non-invasive stress test suggestive of myocardial ischemia. To 
limit clinical heterogeneity, individuals suffering from acute illnesses other than acute coronary 
syndrome, chronic non-cardiac diseases and a history of malignancy within the five past years were 
excluded. All participants were completed a detailed questionnaire which gathered information on 
medical history, clinical, and lifestyle factors. Fasting blood samples were obtained by venipuncture in 
the early morning and stored for later analyses. Information on vital status during follow-up was 
obtained from local registries. Death certificates, medical records of local hospitals, and autopsy data 
were reviewed independently by two experienced clinicians who were blinded to patient characteristics 
and who classified the causes of death. Coronary heart disease (CHD) at baseline was defined as the 
presence of a visible luminal narrowing (>50% stenosis) in at least one of 15 coronary segments 
according to the classification of the American Heart Association. These patients were included in the 
current analysis.  Samples were genotyped on an Affymetrix 6.0 array. Study protocols were approved 
by the ethics committee of the "Landesärztekammer Rheinland-Pfalz" and the study was conducted in 
accordance with the "Declaration of Helsinki”. Informed written consent was obtained from all 
participants.  
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34) MDCS - Malmo Diet and Cancer Study 
Malmö Diet and Cancer is a prospective, community-based cohort study including 30,447 middle-aged 
participants from southern Sweden that underwent a baseline examination in 1991-1996. Participants 
filled out a questionnaire, underwent anthropometric measurements, and donated peripheral venous 
blood samples. Prevalent and incident diagnoses of myocardial infarction were identified by record 
linkage to national registers using personal identification numbers, The Swedish Hospital Discharge 
Register (HDR) and the Swedish Cause of Death Register (CDR) as described previously 33. Subjects 
undergoing percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery for 
coronary heart disease were also identified from the HDR. In total, 2505 subjects were diagnosed with 
myocardial infarction during follow-up and were included in the current study. A total of 2041 
individuals without infarction but undergoing PCI or CABG for coronary disease were also included. 
Information on death during follow-up was obtained from the CDR and cardiovascular mortality was 
defined as death from any code in the category of the International Classification of Disease 10th 
edition. All participants are residents of European descent. The local ethics committee approved of the 
study and written informed consent was obtained from all participants 33.  
 
35) NE_POLAND - North East Poland Myocardial Infarction Study 
The North East Poland Myocardial Infarction Study included 652 patients with ST-elevation myocardial 
infarction (STEMI) who survived the first 48 hours after hospital admission. They were all hospitalized in 
the years 2001-2005 and were subjected to log-term follow-up (mean 7.2 ± 2.8 years). Six hundred and 
three patients with completed follow-up and successful genotyping were included in the final 
analysis. All participants are residents of European descent. The local ethics committees have approved 
the protocol of the study. A written informed consent was obtained from all participants 34.  
 
36) NEAPOLIS – NEAPOLIS CAMPANIA ITALIA 
Neapolis is a cohort study of 1394 caucasian patients schedule to undergo elective DES implantation at 
the Clinica Mediterranea (Naples, Italy) between January 2008 and January 2010. One year follow up 
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was available for 75% of the patients. Exclusion criteria were either non-ST-elevation or ST-
elevation myocardial infarction; cardiogenic shock; allergy/intolerance to aspirin and/or clopidogrel; 
serious bleeding or bleeding diathesis; platelet count ≤75.000/mm3; planned or undelayable 
noncardiac surgery; prior percutaneous coronary intervention (PCI) or coronary artery bypass 
graft; severe liver disease (e.g., cirrhosis or portal hypertension); and life expectancy <1 year due 
to other medical conditions. All enrolled patients gave informed consent prior to the index 
procedure. Diabetes mellitus (DM) was diagnosed according to current guidelines. Chronic 
kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) <60ml/min/1.73m2. 
This study was approved by the local ethic committee 35. 
 
37) OHGS longitudinal - Ottawa Heart Genomics Study longitudinal  
A total of 956 individuals were recruited to The Ottawa Heart Genomics Study (OHGS) longitudinal from 
the John and Jennifer Ruddy Canadian Cardiovascular Genetics Centre at The University of Ottawa Heart 
Institute, Ottawa, Canada, between 2010 and 2013, when recruitment ended. Recruited individuals 
were later sent a survey to follow-up on risk factors and behaviours related to CAD and hypertension. 
Participants with both survey and GWAS data available for the Lp(a) locus were included in the analysis. 
Institutional Research Ethics Board (REB) approval was obtained for this study. A total of 755 individuals 
participated in the survey and of those there were 522 with GWAS data available. Information related to 
cause of death of the patients during follow-up were obtained, with prior patient approval, from 
physician(s) at The University of Ottawa Heart Institute and/or any other institution were the patient 
would have sought medical attention for their cardiac condition. Median follow-up was 1.76 years with 
21% of those recruited not participating in the follow-up survey. Cardiovascular mortality was defined as 
death related to CAD, death due to valve failure and death due to stroke. 
 
38) PERGENE - Perindopril Genetic Association Study 
The PERGENE study is a substudy of the EUROPA-trial 36 that will investigate genetic determinants of the 
treatment effect of ACE-inhibition in all subject. The EUROPA trial was a randomized, double-blind, 
placebo-controlled clinical trial, with 12,218 patients who were randomized to perindopril versus 
placebo after a 4-week run-in period. Mean follow-up was 4.2 years. The study recruited men and 
women aged ≥18 years without clinical evidence of heart failure and with evidence of coronary artery 
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disease documented by either previous MI, percutaneous or surgical coronary revascularization or 
angiographic evidence of ≥70% narrowing of ≥1 major coronary artery. Men were also recruited if they 
had a history of chest pain and a positive exercise test or regional wall motion abnormalities during 
stress echocardiography or nuclear scintigraphy or with transient perfusion defects during scintigraphy 
perfusion imaging. All participants are residents of European descent (majority Caucasian). The local 
ethics committees have approved EUROPA/PERGENE. A written informed consent was obtained from all 
participants 37. 
 
39) PLATO - The study of Platelet Inhibition and patient outcomes 
The PLATO trial was an international randomized double blind, double dummy phase III study comparing 
ticagrelor with clopidogrel in patients with either ST-elevation MI intended for primary PCI or with non-
ST-elevation ACS, regardless if aimed for an initial invasive or non-invasive treatment strategy. A total of 
18,624 patients were included. Follow up was 6 to 12 months, with a median of 9 months. The outcome 
events were centrally adjudicated and included cardiovascular and total death, myocardial infarction, 
stent thrombosis, stroke and major bleeding. DNA for genetics analyses is available from 9340 patients 
38. 
 
40) PMI - Post Myocardial Infarction Study  
The Post Myocardial Infarction Study (PMI) is a cohort study of 1,063 patients with acute myocardial 
infarction admitted to Christchurch Hospital (New Zealand) from 1994-2001. Inclusion criteria were 
acute myocardial infarction (ST-elevation myocardial infarction and non-ST-elevation myocardial 
infarction) as defined by the presence of typical cardiac symptoms, ischaemic change on ECG in 2 or 
more contiguous leads and peak elevation of creatinine kinase of at least twice normal 
(400U/L). Anthropometric and clinical measures, including echocardiography and a large number 
of neurohormonal markers, were documented during the index hospital admission Clinical outcomes 
were recorded from the New Zealand Health Information Service over a median 9.3 years after 
admission (maximum 13.4 years). The study was approved by the Canterbury Ethics Committee 
(CTY/94/08/783/AM04) and all patients provided written informed consent. The study was registered on 
the Australian New Zealand Clinical Trials Registry (ACTRN12606000212550).   
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41) POPular – The POPular Study 
POPular is a prospective, observational, single-center cohort study of 1069 (75% male, mean age 64 
years) consecutive patients taking clopidogrel plus aspirin or vitamin K antagonists undergoing elective 
coronary stent implantation between December 2005 and December 2007. The purpose of this study 
was to investigate whether the level of platelet inhibition as assessed with five point-of-care platelet 
function assays correlates with clinical (periprocedural) outcomes such as acute myocardial infarction, 
death, target Vessel revascularization and/or stroke in patients undergoing elective percutaneous 
coronary intervention 39. All participants are residents of European descent. The local ethics committee 
approved conduct of the POPular study. A written informed consent was obtained from all participants. 
 
42) POPular Genetics – The POPular Genetics Study 
POPular Genetics is a new cohort study of individuals with ST-segment elevation myocardial infarction 
(STEMI) undergoing primary percutaneous coronary intervention (PCI).  Further details are due to be 
published in due course. 
 
43) PROSPER - Prospective Study of Pravastatin in the Elderly at Risk 
PROSPER was a randomized, double-blind, placebo-controlled trial of pravastatin treatment in 5,804 
elderly patients with pre-existing vascular disease or at significant risk, that ran between 1997 and 1999. 
The patients were randomized for treatment with 40 mg pravastatin/day or placebo in 3 centers: Cork 
(Ireland), Glasgow (Scotland) and Leiden (the Netherlands) 40. All participants were residents of 
European descent. The local ethics committees approved PROSPER. Written informed consent was 
obtained from all participants. For the purposes of the GENIUS study, 439 patients from PROSPER with 
known coronary heart disease (at baseline) who were allocated to placebo were included.  
 
44) RISCA - Recurrence and Inflammation in the Acute Coronary Syndromes Study 
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The RISCA cohort consists of 1210 consecutive patients recruited from four tertiary and four Canadian 
community hospitals (seven in Quebec and one in New Brunswick). To be eligible, patients had to have 
an urgent admission to the hospital with a diagnosis of either acute MI or unstable angina. Of the 1210 
patients enrolled, 1054 provided consent for genetic testing and 14 patients were excluded because of 
missing covariates, resulting in a final sample of 1040 patients for analysis. Follow-up occurred at 1 
month via outpatient visit and at 1 year. All clinical data and events were verified by on-site visits and 
examination of all necessary supporting documents. Finally, all prospective and potential outcomes 
were centrally adjudicated independently by 2 cardiologist investigators. 
 
45) SHEEP - Stockholm Heart Epidemiology Program 
The Stockholm Heart Epidemiology Program (SHEEP) was originally designed as a case-control study 
aiming at studying risk factors of first time myocardial infarction. Between Jan 12, 1992 and Jan 12, 
1994, all incident myocardial infarction events among men and women aged between 45 and 70 years 
and who were Swedish citizens residing in Stockholm county were identified. The identification of 
female cases continued for another year: from Jan 13, 1994 to Dec 31, 1994. The rate of study 
participation among 28-day survivors of myocardial infarction was 87%. The patients were mainly 
identified through a special organization set up at the 10 emergency hospitals within Stockholm county. 
Follow-up data concerning recurrent cardiovascular disease events and death up to December 31, 2012 
have been extracted from national registers. Informed consent was obtained from all participants and 
the local ethics committee has approved the SHEEP. Details about the study design, including criteria for 
diagnosis of MI, have been described previously 41. 
 
46) SMART – Second Manifestations of ARTerial disease 
The Second Manifestations of ARTerial disease (SMART) study is an ongoing prospective cohort study at 
the University Medical Center Utrecht (UMCU) in the Netherlands. From September 1996 onwards, 
≥12,000 patients were referred to the UMCU with clinically manifested vascular disease (coronary heart 
disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm) or vascular 
risk factors (dyslipidemia, hypertension or diabetes mellitus) and were asked to participate in the study. 
Written informed consent was obtained from all patients.    
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After inclusion, patients underwent a standardized vascular screening protocol consisting of a health 
questionnaire including medical history and risk factors, physical examination and laboratory testing. All 
patients are biannually asked to fill in a short questionnaire regarding hospitalization and outpatient 
clinical visits. If a patient reports a possible event, all available relevant data are collected and an 
outcome committee of three staff members assesses whether study outcomes (primary events: 
myocardial infarction, stroke and vascular death) occurred 42.  
 
47) STABILITY - Stabilization of Atherosclerotic Plaque by Initiation of Darapladib 
Therapy trial 
The STABILITY trial was an international prospective randomised, double-blind of darapladib versus 
placebo in patients with stable coronary heart disease and an indicator of increased risk. 15,828 patients 
were included. Follow-up was 3 – 5 years with a median of 3.7 years. The outcome events were centrally 
adjudicated and contained cardiovascular and total death, myocardial infarction and stroke. DNA for 
genetics analyses is available from 10,786 patients 43.   
 
48) THI - Texgen 
TexGen is a collaborative, prospective genetic registry which enrolls patients with any personal history 
of cardiovascular disease, who seek care at several institutions within the Texas Medical Center 
including the University of Texas Health Science Center, The University of Texas M.D. Anderson Cancer 
Center, Baylor College of Medicine and their affiliated hospitals, and the Texas Heart Institute at St. 
Luke's Episcopal Hospital. The registry includes patients presenting with ACS and those undergoing 
CABG surgery (with or without valve surgery procedures) from September 2001 through September 
2008. Written informed consent was obtained from all study participants. 
 
49) TNT - Treating to New Targets 
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The TNT study was a randomized, double-blind clinical trial to compare high-dose to moderate-dose 
atorvastatin as secondary prevention in patients with established stable CAD defined as previous MI, 
previous or present angina with objective evidence of atherosclerotic CAD, or a history of coronary 
revascularization. A total of 10,001 patients were randomized to treatment with either 10 mg of 
atorvastatin or 80 mg of atorvastatin daily from 256 sites in 14 countries between July 1998 and 
December 1999. Mean follow-up was 4.9 years. The study's primary endpoint was the occurrence of a 
first major cardiovascular event, defined as death from CAD, nonfatal nonprocedural-related MI, 
resuscitation, or fatal or nonfatal stroke. The study was performed under the terms of the Declaration of 
Helsinki and the study protocol was approved by the local review boards or ethics committees and all 
patients gave written informed consent. The genetic study was approved by the Montreal Heart 
Institute ethics committee 44.  
 
50) TRIUMPH - Translational Research Investigating Underlying Disparities in Acute 
Myocardial Infarction Patient’s Health Status 
The TRIUMPH study was designed to explore racial differences in prognosis for myocardial infarction 
patients. Between June 1, 2005 and December 31, 2008, 31,567 patients with MI were prospectively 
screened of whom 6,152 had an eligible MI. Of eligible patients, 4,340 (71%) patients were enrolled into 
TRIUMPH from across 24 US centers with genetic data available for 2,979 (69%) of patients. Centralized 
follow-up interviews sought to quantify patients’ post-discharge care and outcomes, with a focus on 
their health status (symptoms, function, and quality of life). At 1, 6 and 12 months, 23%, 27% and 24% 
were lost to follow-up. Vital status was available for 99% of patients at 12-months 45.  
 
51) UCORBIO - Utrecht Coronary Biobank Study 
The Utrecht Coronary Biobank Study (UCORBIO) enrolled 2,591 patients who underwent coronary 
angiography for any indication at the University Medical Center Utrecht (UMCU). Baseline assessment 
and blood sampling took place between 2011 and 2014. Patients were followed up (maximum: 3years) 
for the occurrence of major adverse cardiovascular events (stroke, myocardial infarction, coronary 
revascularization, death). The study was approved by the Ethics Committee of the UMCU and was 
conducted according to the Declaration of Helsinki.   
UCORBIO is registered with clinicaltrials.gov (ID: NCT02304744)  
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52) UCP - Utrecht Cardiovascular Pharmacogenetics Study 
Participants of the Utrecht Cardiovascular Pharmacogenetics (UCP) studies were enrolled through the 
Dutch population‐based Pharmaco‐Morbidity Record Linkage System (PHARMO) database. The 
PHARMO database links drug dispensing history from a representative sample of Dutch community 
pharmacies to the national registry of hospital discharge diagnoses. Several nested case-control studies 
to assess the interaction between SNPs, drug use and the risk of myocardial infarction were performed 
using UCP data 46, 47. The UCP studies received ethical approval from the Medical Ethics Committee of 
the University Medical Center Utrecht, the Netherlands. A written informed consent was obtained from 
all participants. 
 
53) UKB - UK Biobank 
UK Biobank is a large-scale cohort study, including 502,655 participants aged between 40-69 years. 
Study participants were recruited from 22 recruitment centres across the United Kingdom between 
2006 and 2010 48. A sub-sample of the cohort (N = 10,287) of European descent with coronary heart 
disease at baseline, phenotyped using ICD10 and OPS codes, were included in GENIUS analyses. 
 
54) VHS - Verona Heart Study 
The Verona Heart Study (VHS) is a regional survey aimed to search for new risk factors (RFs), particularly 
genetic RFs, for coronary artery disease (CAD) in subjects with angiographic documentation of their 
coronary vessels. Since 1996, the VHS has recruited over 2,500 adult patients of both sexes from those 
referring to the University Hospital of Verona and undergoing to coronary angiography. The VHS 
includes either patients with angiographically proven CAD or controls with completely normal coronary 
arteries, being initially submitted to coronary angiography for reasons other than CAD (mainly valvular 
heart disease, CAD-free group). Prospective data are collected with a median follow-up of 5 years.   
 
55) VIVIT - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) 
Study 
27 
 
The VIVIT-study has consecutively recruited 1,804 Caucasian patients who underwent coronary 
angiography for the evaluation of established or suspected CAD at the Academic Teaching 
Hospital Feldkirch (Austria) between September 1999 and April 2008. Patients undergoing coronary 
angiography for other reasons were not enrolled. In particular, no patients with acute coronary 
syndromes were enrolled. The ethics committee of the University of Innsbruck approved the study, and 
all participants gave written informed consent 49.   
 
56) WARSAW ACS - Warsaw ACS Genetic Registry 
Warsaw ACS genetic registry comprised of unselected, consecutive patients with ACS, (with STEMI and 
NSTEMI/UA) hospitalized in the years 2008-2011 in I Chair and Department of Cardiology, Medical 
University of Warsaw (Warsaw, Poland). Patients were treated according to the local hospital protocol, 
which was based on STEMI ESC guidelines. This involved primary percutaneous coronary intervention 
(pPCI) as a default treatment strategy in majority of patients. 
The protocol was accepted by the Ethics Committee of the Medical University of Warsaw. Informed 
patient consent was obtained from all participants included in the registry. The analyzed end-point was 
total long-term mortality. Data concerning survival was retrieved from the local population registry run 
by a Government Office. 
 
57) WTCCC - Welcome Trust Case Control Consortium CAD study 
Cases were European Caucasians who had a validated history of either myocardial infarction (MI) or 
coronary revascularisation (coronary artery bypass surgery or percutaneous coronary angioplasty) 
before their 66th birthday. Recruitment was carried out on a national basis through: (i) responses to a 
sustained UK-wide media campaign, (ii) through responses to posters placed within hospitals and GP 
(family physician) surgeries throughout the UK, and (iii) in a pilot-phase contacting patients listed on 
computer based coronary artery disease databases, in the two lead centres (Leeds and Leicester). The 
recruitment period was from April 1998 to November 2003. The primary purpose was to recruit families 
with two or more available siblings with CAD, for a linkage study called the BHF Family Heart Study (BHF-
FHS) 50. During the course of the project we however, also recruited subjects with CAD who had a family 
history of premature CAD (in parents or another sibling), but in whom a further affected sib was not 
available, for a related project called the GRACE Study 51. 
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2 Supplemental Tables  
 
Supplemental Table 1: Additional phenotypes available in GENIUS-CHD studies. X denotes availability of 
the relevant phenotype; ECG = electrocardiogram; MRI = magnetic resonance imaging; IMT = intima 
media thickening; ACE = Angiotensin Converting Enzyme; CRP = C=Reactive Protein;  
 
Supplemental Table 2: Samples available in GENIUS-CHD studies. X denotes availability of the relevant 
sample type; RNA = ribonucleic acid; DNA = deoxyribonucleic acid; EDTA = Ethylenediaminetetraacetic 
acid 
 
Supplemental Table 3: DNA & Genotyping platform details for GENIUS-CHD studies.  
 
Supplemental Table 4: Subsequent events and follow up data available in GENIUS-CHD studies. X 
denotes availability of the relevant event/endpoint; CVD = cardiovascular disease; CHD = coronary heart 
disease; MI = myocardial infarction; mean and (SD) provided for follow up length. 
 
Supplemental Tables 5 - 7: Random effects Meta-analyses estimates for each of age, sex and smoking.   
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Supplemental Table 1. Availability of phenotypes in studies contributing to 
GENIUS-CHD consortium. 
 
Alias Medications Biomarkers Bloods Imaging Vascular 
Function 
Scales 
 
A
n
ti
-p
lt
 
B
et
a
 b
lo
ck
er
 
A
C
E 
In
h
ib
it
o
r 
H
s-
C
R
P
 
Lp
(a
) 
IL
-6
 
H
b
 
fa
st
in
g
 g
lu
c 
A
LT
 
A
n
g
io
g
ra
p
h
y 
Ec
h
o
 
C
a
rd
ia
c 
M
R
I 
A
rt
 s
ti
ff
n
es
s 
C
a
ro
ti
d
 IM
T 
A
B
 In
d
ex
 
Q
u
a
lit
y 
o
f 
Li
fe
 
P
h
ys
ic
a
l 
a
ct
iv
it
y 
So
ci
o
 e
co
n
o
m
ic
 
4C X X X X 
     
X X X 
   
X 
 
X 
AGNES 
 
X X X 
 
X X X X 
         
ANGES 
 
X X X 
 
X X X X 
         
ATVB X X X 
    
X 
 
X 
        
CABGenomics  X X 
     
X X X 
    
X X X 
CARDIOLINES X X X X X X X X X X X X X 
     
CDCS X X X X X 
 
X X 
 
X X 
     
X 
 
COGEN X X X X X 
 
X X X X X 
      
X 
COROGENE X X X X 
  
X 
 
X X X 
       
CTMM X X X X 
 
X X X X X 
    
X 
   
CURE X X X X 
 
X X X X 
      
X X X 
EGCUT X X X                           X X 
EMORY X X X X 
 
X X 
 
X X X 
    
X X X 
ERICO X X X X 
 
X X X X X X 
 
X X X X X X 
FASTMI2005 X X X X 
  
X 
  
X 
        
FINCAVAS  X X X 
 
X X X X X 
      
X 
 
FRISCII X X 
 
X 
 
X X 
           
GENDEMIP X X X X 
  
X X X 
         
GENEBANK X X X X X X X X 
 
X X 
     
X X 
GENESIS-PRAXY X X X X X X X X 
 
X 
     
X X X 
GENOCOR X X X X X 
 
X X X X X 
     
X X 
GEVAMI X X X X 
  
X X 
 
X X X 
    
X X 
GoDARTSincident  
                 
GoDARTSprevalent X X X X 
 
X 
 
X X 
         
GRACE_B X X X 
  
X 
            
GRACE_UK X X X X 
 
X X X X 
         
IDEAL X X X 
  
X X X X 
         
INTERMOUNTAIN X X X X 
  
X X X X X X 
      
INVEST X X X 
            
X 
  
JUMC X X X X 
  
X X 
          
KAROLA X X X X X 
 
X X 
 
X 
     
X X X 
30 
 
Alias Medications Biomarkers Bloods Imaging Vascular 
Function 
Scales 
 
A
n
ti
-p
lt
 
B
et
a
 b
lo
ck
er
 
A
C
E 
In
h
ib
it
o
r 
H
s-
C
R
P
 
Lp
(a
) 
IL
-6
 
H
b
 
fa
st
in
g
 g
lu
c 
A
LT
 
A
n
g
io
g
ra
p
h
y 
Ec
h
o
 
C
a
rd
ia
c 
M
R
I 
A
rt
 s
ti
ff
n
es
s 
C
a
ro
ti
d
 IM
T 
A
B
 In
d
ex
 
Q
u
a
lit
y 
o
f 
Li
fe
 
P
h
ys
ic
a
l 
a
ct
iv
it
y 
So
ci
o
 e
co
n
o
m
ic
 
LIFE-Heart X X X X X X X 
 
X X X 
  
X X 
 
X 
 
LURIC X X X X X X 
 
X X X X 
     
X 
 
MDCS X X X X 
 
X X X 
  
X 
 
X X 
  
X X 
NE_POLAND X X X 
   
X 
  
X X 
       
NEAPOLIS X X X X 
  
X X X 
         
OHGS X X X X 
 
X X X X X 
        
PERGENE X X X 
               
PLATO X X 
 
X 
 
X X 
  
X 
     
X 
  
PMI X X X 
   
X 
   
X 
       
POPular  X X X X 
 
X X 
 
X X 
        
POPular Genetics X X X X 
  
X 
 
X X X 
    
X 
  
PROSPER X X X X X X 
 
X X 
        
X 
RISCA X X X X X X 
    
X 
       
SHEEP X X 
 
X X X 
 
X 
       
X X X 
SMART X X X X 
 
X X X X 
    
X X X X X 
STABILITY X X 
 
X 
 
X X 
           
THI X X X 
   
X X 
 
X 
       
X 
TNT X X X 
 
X X X X X 
       
X 
 
TRIUMPH X X X X 
 
X X X X X X 
    
X X X 
UCORBIO  X X X 
 
X 
  
X X X 
    
X X X 
UCP X X X X 
 
X X X X 
       
X 
 
UKB X X X X X X X X X     X       X X X 
VHS X X X X X 
 
X X X 
         
VIVIT X X X X X 
  
X X X 
       
X 
WARSAW ACS  
  
X 
 
X X X X X X 
       
WTCC X X 
 
X 
 
X X X X 
         
 
Additional phenotypes available in GENIUS-CHD studies. X denotes availability of the relevant 
phenotype; ECG = electrocardiogram; MRI = magnetic resonance imaging; IMT = intima media 
thickening; ACE = Angiotensin Converting Enzyme; CRP = C=Reactive Protein;  
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Supplemental Table 2. Availability of stored samples in studies contributing to 
GENIUS-CHD. 
Alias Blood-
Edta 
Serum Plasma RNA DNA/ 
Buffy 
Coat 
Urine 
4C 
 
X X X 
  
AGNES 
      
ANGES 
      
ATVB X 
 
X 
   
CABGenomics X X X X X 
 
CARDIOLINES X X X X X 
 
CDCS 
  
X 
 
X 
 
COGEN X X 
    
COROGENE X X X 
 
X 
 
CTMM X 
 
X X X 
 
CURE X X X 
   
EGCUT X X X X X   
EMORY 
 
X X X 
  
ERICO 
 
X X X 
 
X 
FASTMI2005  X X 
   
FINCAVAS X X X 
 
X 
 
FRISCII X X X 
   
GENDEMIP  
 
X 
 
X 
 
GENEBANK X X X 
   
GENESIS-PRAXY X X X 
   
GENOCOR X X X 
   
GEVAMI X 
 
X 
 
X 
 
GoDARTSincident X X X 
 
X X 
GoDARTSprevalent  
     
GRACE_B 
    
X 
 
GRACE_UK  
     
IDEAL 
  
X 
 
X 
 
INTERMOUNTAIN  
 
X 
 
X 
 
INVEST 
      
JUMC 
 
X X 
 
X 
 
KAROLA X X X 
 
X 
 
LIFE-Heart X X X X X 
 
LURIC X 
 
X 
   
MDCS X 
 
X 
   
NE_POLAND X 
     
NEAPOLIS X 
 
X 
 
X 
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Alias Blood-
Edta 
Serum Plasma RNA DNA/ 
Buffy 
Coat 
Urine 
OHGS 
 
X X 
 
X 
 
PERGENE X X X 
 
X X 
PLATO 
 
X X 
   
PMI 
    
X 
 
POPular  X 
   
X 
 
POPular Genetics X 
     
PROSPER X 
 
X 
 
X 
 
RISCA X 
 
X 
   
SHEEP 
 
X X 
   
SMART X X X 
 
X X 
STABILITY  
     
THI X X X 
   
TNT X 
 
X 
 
X 
 
TRIUMPH X X X 
 
X 
 
UCORBIO  X X 
 
X 
 
UCP X 
     
UKB X X X X X X 
VHS 
 
X X 
 
X 
 
VIVIT X X X 
  
X 
WARSAW ACS X 
     
WTCC 
 
X X 
   
 
Samples available in GENIUS-CHD studies. X denotes availability of the relevant sample type; RNA = 
ribonucleic acid; DNA = deoxyribonucleic acid; EDTA = Ethylenediaminetetraacetic acid 
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Supplemental Table 3. Genotyping and imputation of studies contributing to 
GENIUS-CHD consortium. 
Alias Main Genotyping platform(s) Imputation  
4C Custom - 
AGNES Illumina Human610k-Quad v1 array - 
ANGES Metabochip - 
ATVB Affymetrix 6.0 GeneChip - 
CABGenomics Sequenom - 
CARDIOLINES  
 
CDCS Sequenom and Taqman assays - 
COGEN Human CoreExome BeadChip (illumina) HRC v 1.1 
COROGENE Illumina Human610k-Quad - 
CTMM Affymetrix Axiom tx - 
CURE Taqman assay - 
EGCUT IllumniaInfiumCoreExome-24, OmniExpress, Human370CNV, 
GlobalScreeningArray 
1000 Genomes 
(Phase 3) 
EMORY Multiplex or taqman - 
ERICO Affymetrix axion - 
FASTMI2005 Applied Biosciences Inc - 
FINCAVAS Metabochip, n = 2278, CoreExome, n = 926 - 
FRISCII 
 
- 
GENDEMIP Taqman assay - 
GENEBANK Affymetrix 6.0 GeneChip - 
GENESIS-PRAXY Sequenom: Platform: iPLEX® Gold Genotyping Technology Taqman: 
Platform: TaqMan® Genotyping Technology (Applied Biosystems) 
- 
GENOCOR High resolution melting curve analysis-LC Green and a Light Scanner 
(Idaho Tech) 
- 
GEVAMI Illumnia Global Screening Array  HRC version 
r1.1 panel 
GoDARTSincident Affy; Affy1KG; Illumina; Illumina 1KG; broad - 
GoDARTSprevalent  
 
GRACE_B Sequenom  (734 samples) - 
GRACE_UK Sequenom - 
IDEAL Sequenom MassArray Maldi-TOF System; Illumina MEGA - 
INTERMOUNTAIN Applied Biosciences Inc - 
INVEST Taqman; Illumina IBC; Illumina OmniExpress - 
JUMC TaqMan™ Real-Time PCR Assays (7900HT Fast Real Time System or 
OpenArray NT cycler) 
- 
KAROLA restriction fragment length polymorphism (RFLP) - 
LIFE-Heart Affymetrix Axiom CADLIFE (CEU+custom content) or Affymetrix Axiom 
CEU 
IMPUTE2 
LURIC Affymetrix 6.0 IMPUTE2 
MDCS Sequenom MassArray or Illumina Omni Express Exome - 
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NE_POLAND ABI 7500 real time PCR - 
NEAPOLIS GENOTYPING 7900HT Fast Real-Time PCR System - 
OHGS Affymetrix Axiom - 
PERGENE Taqman allelic discrimination assays (Applied Biosystems, Foster City, CA, 
USA) and Sequenom (San Diego, CA, USA) mass-spectrometric 
genotyping were used to genotype the selected SNPs, according to the 
manufacturer's protocols. 
- 
PLATO Illumina HumanOmni2.5-4v1 BeadChip, Illumina Infinium 
HumanOmniExpressExome-8 v1 
IMPUTE2 
PMI Sequenom and Taqman assays - 
POPular  TaqMan® Drug Metabolism Genotyping Assay performed on 
StepOnePlus™ system (Applied Biosystems) 
- 
POPular Genetics TaqMan® Drug Metabolism Genotyping Assay performed on 
StepOnePlus™ system (ThermoFisher) 
- 
PROSPER Illumina 660K quad beadchip MACH 
RISCA iPLEX technology on a MassARRAY Compact Analyser - 
SHEEP Illumina Cardiometabochip - 
SMART TaqMan assay - 
STABILITY Illumina HumanOmniExpressExome-8 v1 BeadChip IMPUTE2 
THI Sequenom massarray system, TaqMan - 
TNT Sequenom massarray Maldi-tof System; Illumina MEGA - 
TRIUMPH Infinium HumanCore BeadChip array (GWAS) and the Illumina 
HumanExome v1.1 Analysis BeadChip array (Exome) 
Mach/Minimac 
UCORBIO TaqMan assay - 
UCP 50K Illumina CARe iSelect (IBC) - 
UKB Affymetrix1 UK BiLEVE Axiom™ Array /UK Biobank Axiom™ Array  
VHS iPLEX MassARRAY platform, Multilocus genotyping assay by Roche - 
VIVIT CardioMetaboChip - 
WARSAW ACS TaqMan Assay; ABI 7500 real time PCR platform - 
WTCC Affymetrix GeneChip® Human Mapping 500K Array Set IMPUTE2 
 
DNA & Genotyping platform details for GENIUS-CHD studies.  
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Supplemental Table 4. Subsequent events and ascertainment in studies 
contributing to GENIUS-CHD consortium. 
 
Alias 
A
ll 
C
V
D
 
A
ll 
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se
 D
e
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h
 
C
V
D
 D
e
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h
 
C
H
D
 D
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h
 
C
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 o
r 
M
I 
M
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l I
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n
   
R
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n
 
H
e
ar
t 
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A
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y 
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Ev
e
n
t 
A
sc
e
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ai
n
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n
t 
M
e
th
o
d
 
        
 
  
Linkage? Direct contact? Records? 
Adjudicated 
4C X X X X 
   
 
  
Hospital records and linkage to mortality 
AGNES X X X 
  
X X X 
 
X 
 
ANGES X X X X X X X X X X 
 
ATVB X X X X X X X  
 
X Telephone calls and analysis of clinical 
records 
CABGenomics  X 
     
X 
   
CARDIOLINES X X X 
  
X X X 
 
X 
 
CDCS X X X X X X X X X X New Zealand Health Information System 
COGEN X X X X X X X X X X Nationwide registries; Clinical records; Local 
revascularoization databases; cause of death 
was based on medical records or death 
certificates 
COROGENE  X X X X X X X 
  
Statistics Finland and Hospital discharge 
registry 
CTMM X X X 
  
X 
 
 
  
During follow-up, patients were questioned 
about the occurrence of cardiovascular 
events. Reported events were verified by an 
independent clinical event committee 
CURE X X X X X X X X 
 
X Follow-up data were obtained based on 
linked information to the Estonian Health 
Insurance Fund (EHIF) database, regional 
hospital databases and the Estonian Causes 
of Death Registry 
EGCUT X X X X X X X X X X 
 
EMORY X X X X X 
 
X X 
 
X Follow-up data were collected by personnel 
blinded to the study data through telephone 
interview, chart review and query of the 
Social Security Death Index and State 
records.  Medical records were accessed to 
validate all self-reported events. 
ERICO X X X X X X 
 
 
   
FASTMI2005 X X X X X X X  
 
X Events were adjudicated by a scientific 
committee whose members were unaware of 
patients' medications and biobanking 
measurements 
FINCAVAS X X X X X X X X X X 
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Linkage? Direct contact? Records? 
Adjudicated 
FRISCII X X X X X X X  
  
Clinical follow-up was performed via a visit to 
the outpatient clinic or by a telephone 
interview 
GENDEMIP  X X 
    
 
  
population register 
GENEBANK X X 
   
X X  
 
X 
 
GENESIS-PRAXY X X X 
  
X X X 
 
X Through patient questionnaire 
GENOCOR X X X X X X X X 
 
X Annual mail / telephone interview follow-up, 
clinical records; cause of death was based on 
medical records or death certificates 
GEVAMI X X X X X X X X X X Danish registry, questionnaires, medical 
records; Adjudicated 
GoDARTS 
incident 
X X X X X X X X X X From linked hospitalisation and death recs 
GoDARTS 
prevalent 
X X X X X X X X X X From linked hospitalisation and death recs 
GRACE_B 
  
X X X X X  
   
GRACE_UK X X 
 
X X X X X 
 
X 
 
IDEAL X X X X X X X X X X 
 
INTERMOUNTAIN X X X X X X X X 
 
X clinical referral for cardiac cath, enrollment 
prior to cath, blood obtained at cath 
INVEST X X X 
  
X X  
 
X 
 
JUMC X X X X X X X X X X phone call + medical records 
KAROLA X X X X X X 
 
 
 
X Information on vital status and cause of 
death were retrieved from local health 
authorities; information on non-fatal 
outcomes were ascertained via 
questionnaires from physicians of 
participants 
LIFE-Heart X X X X X X X X 
 
X Mail based follow-up, clinical records 
LURIC X X X X X X 
 
 
 
X 
 
MDCS X X X X X 
  
X X X Nationwide registers 
NE_POLAND  X 
     
 
  
Data retrieved from the local population 
registry run by a Government Office. 
NEAPOLIS X X X X X X X X X X Clinical followup was performed via a visit to 
the outpatient clinic or by a telephone 
interview 
OHGS X X X X X X X  
 
X survey 
PERGENE X X X X X X X X X X 
 
PLATO X X X X X X X X X X Clinical followup was performed via a visit to 
the outpatient clinic or by a telephone 
interview 
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Linkage? Direct contact? Records? 
Adjudicated 
PMI X X X X X X X X X X New Zealand Health Information System 
POPular  X X X X X X X  X X clinical files and telephone contact with the 
patients 
POPular Genetics X X X X X X X X X X clinical files and questionnaires 
PROSPER X X X X X X X X 
 
X general practitioner and self-reported 
RISCA X X X X X X X X 
 
X Hospital admission for UA or MI or post MI 
UA 
SHEEP X X X X X X X X X X Symptoms, cardiac enzymes, ECG 
SMART 
 
X 
   
X X  X X Bi-annual patient questionnaire + hospital 
discharge letters + ECG or brain imaging 
STABILITY X X X X X X X X X X Clinical followup was performed via a visit to 
the outpatient clinic or by a telephone 
interview 
THI X X 
   
X X X 
 
X 
 
TNT X X X X X X X X 
 
X 
 
TRIUMPH  X 
     
 
  
The Social Security Administration Death 
Master File was queried to determine 
patients’ vital status as of 12/31/2010 
(http://www.ntis.gov/products/ssa-dmf.asp) 
and was available for all patients in this 
study.  Of note, this query was performed 
prior to new restrictions and expunging of 
some records from the database. 
UCORBIO X X X 
  
X X X X 
 
patients received questionnaires to obtain 
information on hospital admissions and 
major adverse cardiovascular events (MACE). 
The patients’ general practitioner or the 
reported hospital were asked to confirm 
MACE. If a patient was hospitalized or dies, 
medical records were obtained to evaluate 
the relevance of the event or determine the 
cause of death. 
UCP 
     
X X X X X 
 
UKB X X X X X X X X X X Electronic record linkage (HES/ONS) 
VHS 
 
X X X X X 
 
 
  
Survival status was determined by searching 
in the National Population Register and by an 
ambulatory or telephone survey. Certification 
and date of death were obtained from the 
National Population Register. The causes of 
death were obtained from death certificates 
kept at the Italian Institute of Statistics 
(ISTAT). For non-fatal myocardial infarction a 
review of medical records has been also 
performed. 
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Linkage? Direct contact? Records? 
Adjudicated 
VIVIT X X X X X X X  
 
X National registry (Statistik Austria , Vienna, 
Austria)  review of patient records 
WARSAW ACS  X 
     
 
  
Data retrieved from the local population 
registry run by a Government Office. 
WTCC 
 
X 
     
 
   
 
Subsequent events and follow up data available in GENIUS-CHD studies. X denotes availability of the 
relevant event/endpoint; CVD = cardiovascular disease; CHD = coronary heart disease; MI = myocardial 
infarction; mean and (SD) provided for follow up length  
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Supplemental Table 5: Random Effects meta-analysis estimates for age 
Age Number of 
events 
Number of 
subjects 
OR 2.5% 97.5% 
CHD death or MI 19753 153186 1.152 1.121 1.184 
MI 12569 138689 1.060 1.025 1.096 
Heart Failure 8725 117811 1.295 1.247 1.346 
Revascularization 25712 128444 0.985 0.967 1.004 
Ischaemic Stroke 2035 59934 1.265 1.214 1.319 
Any stroke 5004 136183 1.257 1.225 1.291 
Any CVD 37737 138028 1.127 1.100 1.155 
CHD death 10446 137325 1.368 1.327 1.411 
CVD death 11272 133027 1.392 1.346 1.439 
All cause death 22758 160697 1.386 1.351 1.423 
Supplemental Table 6: Random Effects meta-analysis estimates for sex 
Sex 
Number of 
events 
Number of 
subjects 
OR 2.5% 97.5% 
CHD death or MI 19753 153186 1.152 1.121 1.184 
MI 12569 138689 1.060 1.025 1.096 
Revascularization 25712 128444 0.985 0.967 1.004 
Heart Failure 8725 117811 1.295 1.247 1.346 
Ischaemic Stroke 2035 59934 1.265 1.214 1.319 
Any stroke 5004 136183 1.257 1.225 1.291 
Any CVD 37737 138028 1.127 1.100 1.155 
CHD death 10446 137325 1.368 1.327 1.411 
CVD death 11272 133027 1.392 1.346 1.439 
All cause death 22758 160697 1.386 1.351 1.423 
Supplemental Table 7: Random Effects meta-analysis estimates for smoking 
Smoking Number of 
events 
Number of 
subjects 
OR 2.5% 97.5% 
CHD death or MI 10029 131067 1.413 1.309 1.526 
MI 11859 134487 1.275 1.184 1.373 
Revascularization 24783 124623 1.023 0.972 1.077 
Heart Failure 8335 111961 1.207 1.104 1.318 
Ischaemic Stroke 1908 56454 1.209 1.042 1.403 
Any stroke 4755 132479 1.152 1.016 1.306 
Any CVD 36275 132322 1.140 1.075 1.209 
CHD death 18894 145617 1.315 1.229 1.407 
CVD death 10754 126584 1.417 1.306 1.537 
All cause death 21627 154732 1.499 1.410 1.594 
Random effects Meta-analyses estimates for each of age, sex and smoking (Supp Tables 5,6,7).   
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3 Supplemental Figures 
Supplemental Figure 1: Example QC plot for Body Mass Index  
Quality control plot for BMI. Illustrative example of QC approaches to identify outliers and problems 
with variables explored in federated analyses. BMI is plotted showing by individual study the minimum 
(min); maximum (max); mean; standard deviation (sd) and inter-quartile range (iqr) 
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